Routine proxy notice, no trading signal. Monitor the June 11 meeting for any unexpected voting outcomes or dissident activity, though none is indicated in this filing.
PYXS drugs
PYXS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $1.70entry
- T+1 · 7mo ago +1.18%α +0.96% · $1.72
- T+5 · 6mo ago +32.94%α +31.21% · $2.26
- T+20 · 6mo ago +5.88%α +0.66% · $1.80
- T+60 · 4mo ago +71.18%α +68.07% · $2.91
Price Chart
How similar events traded
Executive Summary
Pyxis Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2024 Annual Meeting of Stockholders, scheduled for June 11, 2024. The agenda includes the election of one Class I director and three Class III directors, and ratification of Ernst & Young as independent auditor. The board recommends a vote FOR all proposals. This is a routine administrative filing with no material financial impact.
Key Financial Metrics
Key Facts
- Annual Meeting of Stockholders scheduled for June 11, 2024
- Record date: April 18, 2024
- Proposal 1: Election of one Class I director (Santhosh Palani) and three Class III directors (John Flavin, Lara Sullivan, Jakob Dupont)
- Proposal 2: Ratification of Ernst & Young LLP as independent auditor for FY 2024
- Board recommends a vote FOR both proposals
- Filing is a notice of internet availability of proxy materials (DEFA14A)
Financial Impact
No financial figures disclosed in this filing
Risk Factors
- No material risks identified from this routine filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-194051 |
| Document: 0001193125-26-194051-index-headers.html | 0001193125-26-194051 |
| Document: 0001193125-26-194051-index.html | 0001193125-26-194051 |
| Document: 0001193125-26-194051.txt | 0001193125-26-194051 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers